Purpose Tau deposition is a key pathological feature of Alzheimer's disease (AD) and other neurodegenerative disorders. The spreading of tau neurofibrillary tangles across defined brain regions corresponds to the observed level of cognitive decline in AD. Positron-emission tomography (PET) has proved to be an important tool for the detection of amyloid-beta (Aβ) aggregates in the brain, and is currently being explored for detection of pathological misfolded tau in AD and other non-AD tauopathies. Several PET tracers targeting tau deposits have been discovered and tested in humans. Limitations have been reported, especially regarding their selectivity. Methods In our screening campaign we identified pyrrolo 
Background
Alzheimer's disease (AD) is the most common age-related neurodegenerative condition [1, 2] . Although the mechanisms of neurodegeneration in AD are not yet fully understood, the major pathological characteristics are plaques, composed of beta-amyloid (Aβ) peptides, and neurofibrillary tangles (NFTs), composed of hyperphosphorylated tubulin associated unit (tau) proteins. There are several validated positronemission tomography (PET) tracers available for the detection of Aβ aggregates in vivo that are recognized as important tools to support the diagnosis and clinical management of AD [3] [4] [5] [6] [7] [8] [9] . Aβ plaque formation occurs early in the disease
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process before the onset of clinical symptoms. As such, Aβ plaque load does not correlate well with cognitive performance, while tau tangles have been shown to have a close correlation to neurodegeneration and track better with cognitive decline. Several PET ligands binding tau deposits ( Fig. 1 ) have been developed [3, [10] [11] [12] [13] [14] [15] [16] [17] . Detailed reviews of currently studied tracers can already be found in the literature [18] [19] [20] .
NFTs are comprised of either paired helical filaments (PHFs) or straight filaments (SFs) [21] . Six tau isoforms are expressed in the human brain, which can be classified into two groups, 3-repeat (3R) or 4-repeat (4R), depending on the number of repeats of the microtubule binding domains [22] [23] [24] [25] .
In AD all six tau isoforms (3R and 4R) are present, and the electron cryo-microscopy (cryo-EM) structure of PHF and SF filament cores reveals that they are made of two identical protofilaments, which adopt a combined cross-β/β-helix structure [23] . The importance of disease-specific folds of tau filaments was recently demonstrated in determining the cryo-EM structure of the neurodegenerative tauopathy Chronic traumatic encephalopathy (CTE) [26] . Though all six tau isoforms are present in AD and CTE, the tau filament folds are different, indicating that the same protein sequences can lead to different aggregates. Other neurodegenerative tauopathies include progressive nuclear palsy (PSP), corticobasal degeneration (CBD) and Pick's disease (PiD), all of which lack Aβ plaques [23] . In contrast to AD, the aggregated tau proteins of PSP and CBD contain only the 4R tau isoform, whereas the aggregated tau protein in Pick bodies of PiD contain only the 3R tau isoform [27] . The cryo-EM structure of tau filaments from PiD shows a novel fold of 3R tau [28] , which is different compared to the 3R/4R-fold found in AD and CTE.
Our goal was to identify a compound which has high affinity to tau aggregates, high selectivity towards pathological tau compared to other targets in the brain, favorable pharmacokinetic properties (fast brain uptake followed by complete washout of any unbound activity), lack of defluorination and lack of potentially image-confounding metabolites. The substitution pattern should support a straightforward introduction of the 18 F label by routine methods. Binding to both 3R and 4R tau deposits, as well as being able to bind to different tau-folds, would be an advantage [29] . This would allow the detection of tau pathology, not only in AD but also in non-AD tauopathies including PSP and PiD [30, 31] . Due to the mixed pathologies in AD, selectivity over Aβ is required for a tau PET tracer. In addition, ligands should not display significant binding to monoamine oxidase A (MAO-A) and MAO-B, as previous ligands have shown significant binding in vitro which may contribute to off-target binding. Thus, we explicitly built screens against these targets in the discovery pathway.
We identified pyrrolo[2,3-b:4,5-c']dipyridine core structures with high affinity for aggregated tau and significantly reduced MAO-A binding properties compared to pyrido [4,3-b] indole derivatives. In order to explore the structure-activity relationship of the fluoropyridine substituent, we synthesized all ten fluoropyridine regioisomers ( Fig. 2) to evaluate the impact of the substitution pattern on tau aggregate binding and off-target profile. These ligands were compared to the related compounds 1 (AV-1451) and 3 ([ 18 F]RO6958948). All compounds were analyzed for tau aggregate binding and off-target binding to Aβ as well as MAO-A and MAO-B in brain homogenate assays. Selected compounds were subsequently radiolabeled with fluorine-18 and characterized for specific binding by autoradiography (ARG) on fresh-frozen normal, AD and tauopathy brain slices. Brain uptake, washout and bone uptake were assessed by microPET in NMRI mice. In order to overcome the limitation of low resolution of 'classical' ARG, selected compounds were radiolabeled with 
Methods

General chemistry methods
All reagents and solvents were obtained from commercial sources and used without further purification. Proton ( 1 H) spectra were recorded on a Bruker DRX-400 MHz NMR spectrometer or on a Bruker AV-400 MHz NMR spectrometer in deuterated solvents. Chemical shifts were reported in δ (ppm) and spin-spin coupling constants as J (Hz) values and signals are designated as follows: (s) singlet, (br-s) broad singlet, (d) doublet, (dd) doublet of doublet, (t) triplet, and (m) multiplet. Mass spectra (MS) were recorded on an Advion CMS mass spectrometer. Flash purification was conducted with a Biotage Isolera One flash purification system using HP-Sil (Biotage) or puriFlash columns (Interchim) and the solvent gradient indicated in the specific examples. Thinlayer chromatography (TLC) was carried out on silica gel plates with UV detection. Preparative thin-layer chromatography (Prep-TLC) was conducted with 0.5 mm or 1 mm silica gel plates (Analtech: Uniplate, F 254 ) and the solvents indicated in the specific examples.
General
F fluorination method
The tracers were synthesized starting from no-carrier-added (n.c.a. In general, assays were performed in PBS containing 0.1% BSA and 2% DMSO. Non-specific binding (NSB) was determined with samples containing radiolabeled tool compound in the presence of assay buffer without biological substrate and competitor. After incubation, samples were filtered under vacuum on equilibrated GF/B UniFilter plates (PerkinElmer) using the FilterMate 196 (PerkinElmer). Afterwards, filters were washed twice with 200 μL chilled buffer. Top and bottom sides of filter plates were sealed, and an imaging plate was placed on top of the filter plates and exposed for 30 min to O/N. Imaging plates were scanned using the BASReader 5000 (Fuji) and quantified with the AIDA software. Specific binding was calculated by subtracting the NSB signal from measured sample signals. The unblocked radiolabeled tracer signal was defined as total binding (TOTB). pIC 50 values were calculated using Prism V7 (GraphPad).
Human tissues used in this study were commercially obtained from Tissue Solutions Ltd., Glasgow, UK.
Autoradiography
Frozen 18 μm thick human brain slices were examined by autoradiography. All slides were equilibrated for at least 1 h in PBS solution prior to use in the experiment. Each brain section was covered with a solution of the 18 F-labeled tracer in buffer. To determine non-specific binding (NSB) and for blocking experiments, non-radioactive test compounds were used in excess (10 μM) and mixed with the 18 F-labeled tracer (0.8-2.4 kBq/μL). Brain sections were incubated with tracer solution at room temperature for 1 h in a humidity chamber, drained thereafter and placed in a slide holder. Slides were washed sequentially with PBS for 1 min; 70% EtOH in PBS for 2 min; 30% EtOH in PBS for 1 min; and PBS for 1 min. Slides were allowed to air-dry before being placed under Fuji imaging plates in imaging boxes for 30 min to overnight exposure. Imaging plates were scanned using BASReader 5000 (Fuji) and resulting images were analyzed using AIDA software.
Micro-autoradiography
Micro-autoradiography (micro-ARG) was performed on frozen human brain sections that were fixed for 15 min at 4°C with 4% formaldehyde (Sigma, 252,549). Frozen tissue from the entorhinal cortex brain region of an AD donor was purchased from an external provider. When indicated, immunostaining was also performed on the same section. Sections were saturated and permeabilized in blocking buffer (PBS, 10% NGS, 0.25% Triton X-100) for 1 h at room temperature and then incubated overnight at 4°C with a mouse conformation-dependent anti-tau antibody (MC1, kindly provided by Peter Davies, Northwell, USA). The primary antibody was diluted at 1/250 in PBS, 5% NGS, 0.25% Triton X-100. The following day, sections were washed three times for 5 min with 1X PBS before incubation with a secondary (goat) anti-mouse antibody labeled with AlexaFluor647 (Jackson, 115-605-166) diluted 1/500 in PBS for 45 min at room temperature, and further washed three times in PBS. Sections were mounted using ProLong Gold Antifade reagent (Invitrogen P36930) and imaged with a Pannoramic 250 Slide Scanner (3DHistech; Hungary) in both bright-field and immunofluorescence mode.
Immunohistochemistry (IHC)
Frozen human brain sections were used for histological analysis. Antibodies used were mouse anti-phospho-tau (clone AT8; Thermo Fisher #MN1020), mouse anti-3R-tau (clone 8E6/C11, Millipore #05-803), mouse anti-4R-tau (hybridoma supernatant of clone ET-3, kindly provided by Peter Davies, Northwell, USA), and biotin-conjugated donkey anti-mouse IgG (Polyclonal, Jackson #715-065-151). Sections were washed with TBS for 5 min, blocked with TBS including 3% donkey serum for 30 min and stained with primary antibodies at 4°C in a humidified chamber overnight. Thereafter, slides were washed three times in TBS for 5 min, blocked with TBS including 3% donkey serum, and incubated with secondary antibody at RT for 1 h. Upon washing (3 × 5 min in TBS), slides were incubated with peroxidase conjugated streptavidin (Jackson #016-030-084) at RT for 30 min and subsequently washed (3 × 5 min TBS) and stained with AEC Single/Plus (abcam #103742) for 15 min. Staining was stopped by incubation in deionized water for 2 min. Slides were mounted in Aqua-Poly/Mount solution (Polysciences #18606), scanned (VMscope, Germany) and analyzed using CaseViewer 2.1 software.
PET imaging
PET imaging studies on healthy NMRI mice were performed using the Inveon small animal PET/CT scanner (Siemens, Knoxville, TN). Animals were anesthetized by ventilation anesthesia using an isoflurane oxygen mixture (100 mL/min, 2-2.5% isoflurane). Approximately 100 μL of tracer solution containing an activity of 8-10 MBq in NaCl (10% EtOH) was injected intravenously (i.v.) into animals (n = 1-5, female, 20-35 g) via the tail vein. PET scans were initiated at the time of injection of the tracer, and PET data were collected for 60 min. The amount of activity in different regions was quantified using region of interest (ROI) analysis. The analyses were done using Inveon Research Workplace (Siemens, Knoxville, TN). Results were reported as percent injected dose per gram tissue (%ID/g).
One initial brain PET imaging study was conducted with compounds 4 and 7 in the non-human primate (NHP) species rhesus macaque (Macaca mulatta) at Invicro LLC (MNI), New Haven, CT, USA.
(181 MBq) was injected i.v. into an anesthetized animal (female, 7.9 kg; 0.01 mg/kg) with intramuscular ketamine (10 mg/kg) and glycopyrrolate administration 2-3 h prior to PET scan. Within the camera, ventilation anesthesia with 1.75% isoflurane was applied. The two studies were performed with the same animal, 3 weeks apart. PET data were acquired for 240 min p.i., and the amount of activity in different brain regions was quantified using ROI analysis.
Results
Chemistry
To enable in vitro and in vivo evaluation, all non-radioactive compounds and the corresponding precursors had to be synthesized (details can be found in the supplemental information). The nitro-group was selected as the leaving group for nucleophilic exchange with 18 F to prepare the corresponding 18 F-labeled compounds. As heteroarenes containing a nitrogen atom are electron-deficient, the nitro groups at the 2-and 4-position of pyridine are amenable to direct nucleophilic substitution with 18 F without an additional activating group [34] . In order to improve the solubility of the nitroprecursors, Boc-or trityl protecting group was introduced at pyrrolo[2,3-b:4,5-c']dipyridine NH-moiety, as both can be readily cleaved by acid at the end of synthesis.
Thus, the 18 F-labeling of reference compounds 3, 4, and 7 having 2-nitro pyridine moieties worked efficiently with decay-corrected radiochemical yields of 13-20% (radiochemical purity 95-100%). The Boc-protected precursor offered some advantages, such as better solubility compared to the described synthesis of [ 18 F]3 using the corresponding unprotected precursor [12] . The 18 F-labeling of compound 9 with 2-nitro pyridine moiety in the precursor gave lower radiochemical yields of 10% (radiochemical purity 100%). As expected, the 18 F-labeling of compounds 5, 6, 8, and 12 having a 3-nitro pyridine or 4-nitro pyridine moiety gave poor decay corrected radiochemical yields of ≤3% (radiochemical purity 95-100%). The 
Misfolded tau binding using AD brain homogenate
To assess binding to pathological tau aggregates in AD brain homogenates, [ 
Looking at the fluoropyridine regioisomers a significant impact regarding their tau aggregate binding properties was found (Table 1) (Table 1) . Taken together, regarding their pharmacokinetic profiles in mouse, compounds 4, 7 and 8 were identified as the best compounds in terms of brain uptake, fast and complete washout from the mouse brain and having no defluorination. Based on the tau binding data obtained with AD brain-derived homogenates and PK data, compounds 4 and 7 were selected for a PK study in NHP rhesus macaque (Macaca mulatta) performed at Molecular Neuroimaging LLC (MNI), New Haven, CT, USA. This pilot NHP PET study confirmed the brain penetration and fast washout from the brain observed in mice. Whole brain peak %ID was 2.5% at 3.5. minutes p.i. with a clearance rate of 0.125 min −1 for compound 4 and 1.8% at 3.5 min p.i.
with a clearance rate of 0.085 min −1 for compound 7.
The fast clearance across all brain regions resulted in standardized uptake values (SUVs) of less than 0.3 at 60 min p.i. for compound 7 (Fig. 3a) . The fast washout from the brain is also visualized in Fig. 3b, demonstrating F]PI-2620 to AD and non-AD tauopathies was further evaluated by autoradiography using AD brain sections from Braak stages I, III and V and non-demented control (NDC) samples (Fig. 4a) . Autoradiography results were compared with immunostaining of identical and/or adjacent brain sections using tau-specific antibodies. In the pathological brain sections analyzed, the area of specific autoradiographic signal of [ (Fig. 4b) . The micro-ARG signal of accumulating silver grains, generated by [
3 H]PI-2620, revealed a region rich in NFT aggregates in the AD brain section examined, recapitulating the immunofluorescence signal of Thioflavin S staining in an adjacent section. More importantly, the binding of [ (Fig. 5a) . Furthermore, MC1 immunostaining of a PSP brain section, labeling tau-positive tangle-like structures, colocalized with the micro-ARG signal of [ 3 H]PI-2620 in the same section, suggesting target engagement to pathological tau aggregates in PSP tissue (Fig. 5b) . However, in the specific brain region examined, very few taupositive structures of tangle-like size were identified. Due to limitations in resolution, we were not able to detect micro-ARG signals colocalizing with MC-1-positive tau aggregates resembling threads or tufted astrocytes.
Discussion
We initiated our PET-ligand search by screening the Morphomer™ library to identify small molecules with suitable target to off-target binding properties. Pyrrolo (Fig. 2) .
Despite the apparent structural similarities of the regioisomers and comparators 1 (AV-1451) and 3 (RO6958498), the different compounds gave rise to a remarkably diverse set of characteristics. The 2-fluoropyridine isomers 9, 10, 11 and 12 displayed lower pIC 50 values, between 7.3-7.5, compared to 3-pyridine and 4-pyridine regioisomers when evaluated for target affinity to aggregated tau (Table 1) . Regioisomers 4, 5, and 7 had the highest affinities with pIC 50 values >8. Compounds 9 and 11 revealed off-target binding to Aβ and were not further pursued. Affinity to MAO-A was found for several compounds (3, 8, 9 , and 10). The pIC 50 value for MAO-A binding of compound 1 (AV-1451) was the highest tested (7.7). Measurable off-target binding to MAO-B in a similar assay employing [ 3 H]deprenyl was also noted for several compounds (9, 10 and AV-1451, 1). All labeling precursors for the 10 regioisomers were prepared. As compounds 10 and 11 failed several radiolabeling attempts, microPET PK data were assessed only for the remaining 8 regioisomers 3, 4, 5, 6, 7, 8, 9, 12 and AV-1451 (1) . While all tested tracers crossed the murine blood brain barrier, the brain uptake values were noticeably different, ranging 18 F]7 in NHP was performed. These NHP data were consistent with the mouse PK and recapitulated the slightly faster washout of compound 4 over 7. Compound 7 showed slightly higher affinity for misfolded tau derived from AD compared to 4. Interestingly, compared to 4, compound 7 displayed superior binding ( (Fig. 4) . In contrast, ligand binding assays using NDC brain tissues revealed an extremely low background binding in brains devoid of pathological misfolded tau. The low off-target binding of PI-2620 was confirmed in NHP studies in which high brain uptake and fast and complete washout was observed, with no obvious off-target binding (Fig. 3) . Brain kinetic data in animal models do not suggest the presence of a brain penetrating lipophilic metabolite, and the analyses of tracer metabolism will be further described in subsequent clinical publications. In in vitro studies [ Table 2) . Off target binding to neuromelanin-and melanincontaining cells, including pigmented neurons in the substantia nigra, was observed for various tau PET tracers, including AV-1451 (1) [37] , and MK-6240 [38] . The same was observed for PI-2620 in the pars compacta of human sections from the substantia nigra (Suppl. Fig. 1 ).
The binding of tau PET ligands to 4R tau aggregates present in PSP and corticobasal degeneration (CBD) is controversial and has been quite challenging. Several tau PET ligands have been reported not to bind to tau deposits in PSP by autoradiography [13, 37, 39] . Schonhaut et al. reported a statistical increase in [18F]AV-1451 (1) uptake in some brain regions including globus pallidus in PSP patients in a clinical trial, although the clinical meaningfulness remains unclear [40] . There are several possible reasons: 1) low affinity of the ligands for 4R tau aggregates/aggregate folds, 2) low density of tau aggregates in PSP tissues, 3) difficulty in distinguishing specific from non-specific binding in basalganglia structures, and 4) heterogeneity of tau aggregation and/or tau aggregate folds in 4R tauopathies. From the preclinical data presented here, PI-2620 clearly binds to tau aggregates/aggregate folds in PSP. Clinical data are required to establish the utility of PI-2620 in non-AD tauopathies.
Thus, [
18 F]PI-2620 is currently being evaluated in several clinical trials to define its pharmacokinetic properties and its metabolic profile in humans to confirm its suitability for imaging pathological tau aggregates/aggregate folds in AD and non-AD tauopathies in vivo. port of the translational imaging team at Invicro LLC, New Haven is greatly appreciated. In memoriam: Dr. Andreas Muhs, † December 2018.
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